GlassScriptPhysician profile
Angel L Roberson
NPI 1497477608
$2,405.57
in general payments reported to CMS, 2019-2025
32 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $563 · 2024: $646 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849 · Education: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.40 |
| Education | $556.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $601.18 | 2024-2025 | Tremfya, Rybrevant |
| Abbvie INC. | $280.32 | 2025 | |
| Seagen INC. | $196.00 | 2023 | |
| Astellas Pharma US INC | $190.95 | 2024 | |
| Ethicon INC. | $120.29 | 2024 | Monarch Platform |
| Takeda Pharmaceuticals U.S.A., INC. | $113.19 | 2023-2025 | Entyvio, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $105.20 | 2023-2025 | Dupixent, Libtayo |
| Emd Serono, INC. | $91.16 | 2024 | |
| Genentech USA, INC. | $78.08 | 2023-2025 | Phesgo, Venclexta, Tecentriq |
| Novartis Pharmaceuticals Corporation | $72.91 | 2023-2024 | Kisqali |
| Ipsen Biopharmaceuticals, INC | $59.60 | 2023-2025 | Iqirvo, Tazverik |
| Pfizer INC. | $56.75 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $43.24 | 2023 | Ultomiris |
| Genzyme Corporation | $41.35 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.61 | 2023-2024 | Keytruda |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25.48 | 2025 | Ojjaara |
| Intercept Pharmaceuticals, INC. | $25.34 | 2025 | |
| Jazz Pharmaceuticals INC. | $25.05 | 2024 | |
| Incyte Corporation | $23.29 | 2023 | Jakafi |
| Adc Therapeutics America, INC. | $23.06 | 2023 | |
| Stemline Therapeutics INC. | $23.04 | 2023 | Orserdu |
| Lilly USA, LLC | $19.34 | 2023 | Jaypirca, Retevmo |
| Gilead Sciences, INC. | $18.21 | 2025 | |
| Taiho Oncology, INC. | $17.82 | 2024 | |
| Pharmaessentia USA Corporation | $17.65 | 2023 | Besremi |
| Pharmacosmos Therapeutics INC. | $17.25 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $16.61 | 2023 | Lynparza |
| Amgen INC. | $14.38 | 2023 | Nplate, Xgeva, Vectibix |
| Morphosys, US INC. | $14.32 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $14.00 | 2023 | Krazati |
| Aimmune Therapeutics, INC. | $13.66 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.